BMEA: Promising phase II diabetes results and next-gen GLP-1 data set for major readouts this year
The presentation highlighted progress on a first-in-class menin inhibitor for diabetes, showing promising phase II results in both Type 1 and Type 2 diabetes, and a next-generation GLP-1 agent with improved tolerability. Key clinical readouts and potential licensing activities are expected within t…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.